Earnings summaries and quarterly performance for GLAUKOS.
Executive leadership at GLAUKOS.
Board of directors at GLAUKOS.
Research analysts who have asked questions during GLAUKOS earnings calls.
Allen Gong
JPMorgan Chase & Co.
4 questions for GKOS
Also covers: ESTA, INGN, IRTC +2 more
Anthony Petrone
Mizuho Group
4 questions for GKOS
Also covers: ADMA, ALC, BSX +22 more
Larry Biegelsen
Wells Fargo & Company
4 questions for GKOS
Also covers: ABT, ALC, AXNX +24 more
Michael Sarcone
Jefferies
4 questions for GKOS
Also covers: ALC, AXGN, CTSO +11 more
Ryan Zimmerman
BTIG
4 questions for GKOS
Also covers: ALC, GEHC, GMED +23 more
Thomas Stephan
Stifel
4 questions for GKOS
Also covers: ALC, RXST, SGHT +1 more
Danielle Antalffy
UBS Group AG
3 questions for GKOS
Also covers: ABT, ATRC, BAX +15 more
David Saxon
Needham & Company
3 questions for GKOS
Also covers: ALC, ALGN, ATEC +11 more
Joanne Wuensch
Citigroup Inc.
3 questions for GKOS
Also covers: ABT, BAX, BDX +18 more
Richard Newitter
Truist Securities
3 questions for GKOS
Also covers: AXNX, DXCM, GMED +18 more
Adam Maeder
Piper Sandler Companies
2 questions for GKOS
Also covers: ABT, AXNX, EW +13 more
Mason Carrico
Stephens Inc.
2 questions for GKOS
Also covers: AKYA, CDNA, CSTL +13 more
Patrick Wood
Morgan Stanley
2 questions for GKOS
Also covers: ALC, BDX, BLCO +17 more
Steven Lichtman
Oppenheimer & Co. Inc.
2 questions for GKOS
Also covers: ALC, ANGO, COO +12 more
K. Gong
JPMorgan Chase & Co.
1 question for GKOS
Also covers: ESTA
Macauley Kilbane
William Blair & Company
1 question for GKOS
Also covers: CBLL, CVRX, IRTC +4 more
Matthew O'Brien
Piper Sandler & Co.
1 question for GKOS
Also covers: APYX, ATEC, ATRC +18 more
Ravi Misra
Truist Securities
1 question for GKOS
Also covers: IART, TFX
Recent press releases and 8-K filings for GKOS.
Glaukos Discusses iDose Launch Progress, Epioxa Strategy, and Financial Outlook at Citi Conference
GKOS
Product Launch
Guidance Update
New Projects/Investments
- Glaukos is transitioning towards generating more pharmaceutical revenue than device revenue, driven by its pipeline and product strategy.
- The iDose launch is progressing, with four of seven Medicare Administrative Contractors (MACs), representing approximately 70% of Medicare lives, now having professional fee schedules for the product. The clinical performance of iDose continues to exceed expectations.
- The company has launched Epioxa, its first rare disease drug for keratoconus, and has built a dedicated organizational foundation for rare disease market access and patient support.
- Glaukos aims for cash flow break-even in the near term and projects operating margins of 30% to 35% in the medium to long term, supported by its high gross margins.
- The traditional MIGS stent business is expected to be "flattish" next year, partly due to iDose cannibalizing some of its growth.
Dec 3, 2025, 6:45 PM
Glaukos Discusses Strategic Shift to Pharmaceuticals, iDose Launch Progress, and Financial Outlook at Global Healthcare Conference
GKOS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Glaukos is transitioning from a microtechnology stent manufacturer to a company with a growing focus on pharmaceutical revenue, highlighted by the recent launch of Epioxa, a rare disease drug for keratoconus.
- The launch of iDose in 2025 has demonstrated strong clinical performance, exceeding expectations, though it faces ongoing challenges with professional fee reimbursement from Medicare Administrative Contractors (MACs); currently, four of seven MACs cover professional fees, representing 70% of Medicare lives.
- The legacy stent and MIGS franchise is projected to be flattish next year, with concomitant MIGS reimbursement expected to decline by low double digits for 2026 on the professional fee side.
- Financially, Glaukos is working towards achieving cash flow break-even in the near term and anticipates reaching 30%-35% operating margins in a mature business.
- The company's pipeline includes a next-generation iDose (TREX) designed for longer duration and an in-office injector system (Trio), both currently undergoing clinical development.
Dec 3, 2025, 6:45 PM
Glaukos Discusses Strategic Shift, iDose Reimbursement, and Financial Outlook for FY 2025
GKOS
Product Launch
Guidance Update
New Projects/Investments
- Glaukos is undergoing a strategic shift, moving from primarily a microtechnology manufacturer of stents (MIGS) to a company with significant pharmaceutical revenue, notably from iDose and the newly launched Epioxa.
- The core MIGS market (excluding iDose) is anticipated to be flattish in FY 2025, partly due to iDose cannibalization. For iDose, four of seven MACs, covering approximately 70% of Medicare lives, currently have professional fee schedules, with the company continuing education efforts for the remaining three.
- Financially, Glaukos is targeting cash flow breakeven in the near term and expects to achieve 30%-35% operating margins in the medium to long term, supported by high gross margins and the retirement of convertible debt.
- The company is also developing iDose TREX, a next-generation iDose designed to deliver twice the drug payload for extended duration, with clinical studies underway.
Dec 3, 2025, 6:45 PM
Glaukos Reports Strong Q3 2025 Results and Provides 2026 Revenue Guidance
GKOS
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Glaukos reported record third-quarter 2025 revenue of $133.5 million, representing mid-to-high 30% growth, driven by U.S. glaucoma revenue of $81 million (57% year-over-year growth) primarily from iDose.
- The company achieved a gross margin of almost 84% and maintained a cash balance of $277.5 million. Gross margin is expected to continue increasing due to the growing mix of high-margin iDose and Epioxa products.
- Glaukos announced preliminary 2026 revenue guidance of $600 million to $620 million, supported by multiple revenue drivers including iDose and the upcoming launch of Epioxa.
- For the Epioxa launch, the product is priced at $78,500 per eye, with an expected net ASP of $65,000-$70,000. The company plans to discontinue Photrexa in a staged process throughout 2026, aiming to significantly increase the number of treated keratoconus patients beyond the current 10,000 annually.
- The core U.S. stent business (non-iDose) is anticipated to be flattish or grow in the low to mid-single digits in 2026, while the broader combo cataract market is expected to return to growth after anniversarying LCD headwinds.
Nov 18, 2025, 4:00 PM
Glaukos Reports Strong Q3 2025 Results, Provides 2026 Revenue Guidance, and Details Epiox Pricing
GKOS
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Glaukos reported Q3 2025 revenues of $133.5 million, a record quarter, with US Glaucoma revenue growing 57% year-over-year to $81 million and International Glaucoma revenue increasing 20% to $29 million. The company achieved a gross margin of almost 84%.
- The company provided preliminary 2026 revenue guidance of $600 million to $620 million, attributing this confidence to multiple revenue drivers, including iDose and the upcoming Epiox launch.
- For its new Epiox product, Glaukos announced a pricing of $78,500 per eye, with an anticipated net average selling price (ASP) ranging from $65,000 to $70,000 after accounting for various discounts and assistance programs.
- Glaukos expects its gross margin to continue increasing due to the growing mix of high-margin iDose and Epioxa products, with a midterm operating margin target of 30-35%. The near-term focus is on achieving cash flow break-even.
Nov 18, 2025, 4:00 PM
Glaukos Reports Strong Q3 2025 Results and Provides 2026 Revenue Guidance
GKOS
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Glaukos reported Q3 2025 revenues of $133.5 million, marking a record quarter, with US Glaucoma revenue growing 57% year-over-year to $81 million, primarily driven by iDose. The company achieved a gross margin of almost 84% and maintained a cash balance of $277.5 million.
- The company provided preliminary 2026 revenue guidance of $600 million-$620 million, anticipating growth from multiple revenue drivers including iDose and the newly launched Epiox.
- For its Epiox product, Glaukos announced a pricing of $78,500 per eye, with an expected net average selling price (ASP) in the range of $65,000-$70,000. The company plans to sunset its VibeX product over 2026, transitioning customers to Epiox.
- Glaukos expects gross margins to continue increasing, driven by the high-margin profiles of iDose and Epioxa, with a midterm operating margin target of 30-35%. Near-term focus is on achieving cash flow break-even while investing in the Epioxa launch.
Nov 18, 2025, 4:00 PM
Glaukos Discusses Epioxa Pricing and iDose Reimbursement Outlook
GKOS
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- Glaukos discussed the Epioxa pricing strategy, which was established to provide value to patients, providers, and payers, while funding patient education and awareness efforts for a rare disease. Gross-to-net considerations include a 23% statutory discount for Medicaid and 340B public hospital systems, and covering out-of-pocket costs for commercial patients.
- For Epioxa volumes, 2026 is expected to be a transition year, with the company aiming to return to and then meaningfully expand beyond the current 10,000 patients (or 18,000-20,000 eyes) treated annually. The patient demographic for Epioxa is primarily commercial or Medicaid patients aged 10-35.
- Regarding iDose reimbursement, Glaukos expressed unchanged confidence in its pricing and long-term patient access despite an upcoming CAC meeting, stating that 2026 guidance already factored in various scenarios related to the CAC outcome.
- The company anticipates Q4 iDose revenue growth may not match Q3's sequential increase due to seasonal shifts in OR time favoring cataract procedures over standalone glaucoma in Q4, though they expect to see continued progress.
- Long-term, iDose is viewed as having a larger peak U.S. sales opportunity than Epioxa due to its target market of 21 million potential ocular hypertensive and glaucomatous eyes, compared to Epioxa's smaller, albeit growing, market.
Nov 12, 2025, 6:20 PM
Glaukos Discusses Q3 Results, 2026 Outlook, and Product Pipeline at UBS Conference
GKOS
Guidance Update
Product Launch
New Projects/Investments
- Glaukos reported record Q3 revenues, including $40 million from iDose, and raised its full-year guidance to $490 million to $495 million.
- The company projects iDose revenue to reach approximately $220 million in 2026, leveraging a significant market opportunity in interventional glaucoma for 12 million actively treated patients.
- The recently approved EPIAXA for keratoconus is expected to be a key growth driver in 2026, requiring substantial investment for market access and patient identification, with a J code anticipated in the latter half of 2026.
- Glaukos aims for cash flow break-even in the near term and 30-35% operating margins in the midterm, while investing in its 14 publicly disclosed pipeline programs and commercial launches.
- Market access for iDose is progressing, with all seven MACs paying on the J code and four of seven MACs having pro fees posted, covering 70% of Medicare lives.
Nov 11, 2025, 3:15 PM
Glaukos Highlights Q3 2025 Financials and Pipeline Progress
GKOS
Earnings
Product Launch
New Projects/Investments
- Glaukos reported Net Sales of $133.537 million and a Non-GAAP Gross Margin of 84% for Q3 2025, with $278 million in cash and equivalents and no debt as of September 30, 2025. The company projects $492.5 million in Net Sales for 2025.
- The company has invested over $800 million in R&D since 2018, focusing on five novel platforms and four therapeutic areas.
- Key product milestones include the FDA approval of Epioxa (Epi-on) for Keratoconus in October 2025, with a launch planned for Q1 2026, and the FDA approval of iDose TR in 2023 for Ocular Hypertension - Glaucoma.
- Glaukos is actively advancing its pipeline with 2025 milestones including EU regulatory approval and commercial launch for iStent infinite, commencement of Phase 2 trials for iLution Blepharitis, and progression of iDose TREX and iLink 3rd Generation clinical programs.
Nov 9, 2025, 11:00 PM
Glaukos Corporation Reports Record Q3 2025 Sales and Raises Full-Year Guidance
GKOS
Earnings
Guidance Update
Product Launch
- Glaukos Corporation reported record third quarter 2025 consolidated net sales of $133.5 million, representing a 38% increase on a reported basis versus the year-ago quarter.
- The company raised its full year 2025 net sales guidance to a range of $490 million-$495 million and introduced a preliminary 2026 revenue guidance of $600 million-$620 million.
- The FDA approved Epioxa, a new corneal cross-linking treatment for keratoconus, with a wholesale acquisition cost (WAC) of $78,500, and commercial availability is expected in Q1 2026.
- Sales of iDose TR reached approximately $40 million in the third quarter of 2025, contributing to strong growth in the U.S. glaucoma franchise.
- Glaukos plans to discontinue Photrexa's commercial availability in 2026, transitioning to Epioxa as the primary treatment option.
Oct 29, 2025, 8:30 PM
Quarterly earnings call transcripts for GLAUKOS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more